8 [46] X. Ming, T. P. Stein, M. Brimacombe, W. G. Johnson, G. H. Lambert, and G. C. Wagner, “Increased excretion of a lipid peroxidation biomarker in autism,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 73, no. 5, pp. 379– 384, 2005. [47] R. Roesler, J. A. Henriques, and G. Schwartsmann, “Gastrin- releasing peptide receptor as a molecular target for psy- chiatric and neurological disorders,” CNS and Neurological Disorders—Drug Targets, vol. 5, no. 2, pp. 197–204, 2006. [48] R. S. Corral, M. A. Iniguez, J. Duque, R. Lopez-Perez, and M. Fresno, “Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells,” Oncogene, vol. 26, no. 7, pp. 958–969, 2007. [49] D. G. Winder and J. D. Sweatt, “Roles of serine/threonine phosphatases in hippocampal synaptic plasticity,” Nature Reviews Neuroscience, vol. 2, no. 7, pp. 461–474, 2001. [50] H. Chen, S. Polo, P. P. Di Fiore, and P. V. De Camilli, “Rapid Ca2+-dependent decrease of protein ubiquitination at synapses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 14908–14913, 2003. [51] J. A. Vorstman, M. E. Morcus, S. N. Duijﬀ et al., “The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 45, no. 9, pp. 1104–1113, 2006. [52] S. Sivagnanasundaram, D. Fletcher, M. Hubank, E. Illing- worth, D. Skuse, and P. Scambler, “Diﬀerential gene expression in the hippocampus of the Df1/+ mice: a model for 22q11.2 deletion syndrome and schizophrenia,” Brain Research, vol. 1139, no. 1, pp. 48–59, 2007. [53] S. E. Mouridsen, B. Rich, T. Isager, and N. J. Nedergaard, “Autoimmune diseases in parents of children with infantile autism: a case-control study,” Developmental Medicine and Child Neurology, vol. 49, no. 6, pp. 429–432, 2007. [54] W. E. Winter and D. Schatz, “Prevention strategies for type 1 diabetes mellitus: current status and future directions,” BioDrugs, vol. 17, no. 1, pp. 39–64, 2003. [55] G. C. Rom a´n, “Autism: transient in utero hypothyroxinemia related to maternal ﬂavonoid ingestion during pregnancy and to other environmental antithyroid agents,” Journal of the Neurological Sciences, vol. 262, no. 1-2, pp. 15–26, 2007. [56] A. K. Sinha, M. R. Pickard, M. J. Hubank et al., “Maternal hypothyroxinemia and brain development: II. Biochemical, metabolic and behavioural correlates,” Acta Medica Austriaca, vol. 19, supplement 1, pp. 49–54, 1992. [57] Y. Omura, “Asbestos as a possible major cause of malignant lung tumors (including small cell carcinoma, adenocarci- noma & mesothelioma), brain tumors (i.e. astrocytoma & glioblastoma multiforme), many other malignant tumors, intractable pain including ﬁbromyalgia, & some cardio- vascular pathology: safe & eﬀective methods of reducing asbestos from normal & pathological areas,” Acupuncture and Electro-Therapeutics Research, vol. 31, no. 1-2, pp. 61–125, 2006. [58] J. Li, B. Huang, X. Shi, V. Castranova, V. Vallyathan, and C. Huang, “Involvement of hydrogen peroxide in asbestos- induced NFAT activation,” Molecular and Cellular Biochem- istry, vol. 234-235, pp. 161–168, 2002. [59] I. M. Thornton, “Out of time: a possible link between mirror neurons, autism and electromagnetic radiation,” Medical Hypotheses, vol. 67, no. 2, pp. 378–382, 2006. Autism Research and Treatment [60] P. K. Manikonda, P. Rajendra, D. Devendranath et al., “Inﬂuence of extremely low frequency magnetic ﬁelds on Ca2+ signaling and NMDA receptor functions in rat hippocampus,” Neuroscience Letters, vol. 413, no. 2, pp. 145–149, 2007. [61] L. Barnard, K. Muldoon, R. Hasan, G. O’Brien, and M. Stewart, “Proﬁling executive dysfunction in adults with autism and comorbid learning disability,” Autism, vol. 12, no. 2, pp. 125–141, 2008. [62] J. D. Runyan, A. N. Moore, and P. K. Dash, “A role for prefrontal calcium-sensitive protein phosphatase and kinase activities in working memory,” Learning and Memory, vol. 12, no. 2, pp. 103–110, 2005. [63] M. Araghi-Niknam and S. H. Fatemi, “Levels of Bcl-2 and P53 are altered in superior frontal and cerebellar cortices of autistic subjects,” Cellular and Molecular Neurobiology, vol. 23, no. 6, pp. 945–952, 2003. [64] J. Zou and F. Crews, “CREB and NF-kappaB transcription factors regulate sensitivity to excitotoxic and oxidative stress induced neuronal cell death,” Cellular and Molecular Neurobi- ology, vol. 26, no. 4–6, pp. 385–405, 2006. [65] H. J. Yoo, I. H. Cho, M. Park et al., “Association between PTGS2 polymorphism and autism spectrum disorders in Korean trios,” Neuroscience Research, vol. 62, no. 1, pp. 66–69, 2008. [66] K. M. Lee, B. S. Kang, H. L. Lee et al., “Spinal NF-kB activation induces COX-2 upregulation and contributes to inﬂammatory pain hypersensitivity,” European Journal of Neuroscience, vol. 19, no. 12, pp. 3375–3381, 2004. [67] D. Q. Ma, M. L. Cuccaro, J. M. Jaworski et al., “Dissecting the locus heterogeneity of autism: signiﬁcant linkage to chromosome 12q14,” Molecular Psychiatry, vol. 12, no. 4, pp. 376–384, 2007. [68] R. K. Weersma, L. E. Oostenbrug, I. M. Nolte et al., “Asso- ciation of interleukin-1 receptor-associated kinase M (IRAK- M) and inﬂammatory bowel diseases,” Scandinavian Journal of Gastroenterology, vol. 42, no. 7, pp. 827–833, 2007. [69] S. D. Steele, N. J. Minshew, B. Luna, and J. A. Sweeney, “Spatial working memory deﬁcits in autism,” Journal of Autism and Developmental Disorders, vol. 37, no. 4, pp. 605–612, 2007. [70] S. Denis-Donini, A. Dellarole, P. Crociara et al., “Impaired adult neurogenesis associated with short-term memory defects in NF-κB p50-deﬁcient mice,” Journal of Neuroscience, vol. 28, no. 15, pp. 3911–3919, 2008. [71] H. Jyonouchi, L. Geng, A. Ruby, and B. Zimmerman-Bier, “Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastroin- testinal symptoms and dietary intervention,” Neuropsychobiol- ogy, vol. 51, no. 2, pp. 77–85, 2005. [72] E. L. Grigorenko, S. S. Han, C. M. Yrigollen et al., “Macrophage migration inhibitory factor and autism spec- trum disorders,” Pediatrics, vol. 122, no. 2, pp. e438–e445, 2008. [73] Y. Gore, D. Starlets, N. Maharshak et al., “Macrophage migra- tion inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex,” Journal of Biological Chemistry, vol. 283, no. 5, pp. 2784–2792, 2008. [74] K. P. Johnson and B. A. Malow, “Sleep in children with autism spectrum disorders,” Current Treatment Options in Neurology, vol. 10, no. 5, pp. 350–359, 2008. [75] M. Yamauchi, S. Tamaki, K. Tomoda et al., “Evidence for activation of nuclear factor kappaB in obstructive sleep apnea,” Sleep and Breathing, vol. 10, no. 4, pp. 189–193, 2006.